Tarsus Pharmaceuticals
- Market cap
- 3.44B
- P/E (TTM)i
- -68.79
- P/Bi
- 9.93
- EPSi
- -1.59
- Div yieldi
- 0.00%
- 52W posi
- 52%
Anonymous reader poll. Unscientific, not investment advice.
About Tarsus Pharmaceuticals
Tarsus Pharmaceuticals, Inc. is a commercial stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. Its product candidate, TP-03, is a novel therapeutic in Phase 2b/3 that is being developed for the treatment of blepharitis caused by the infestation of Demodex mites, which is referred to as Demodex blepharitis. It is also developing TP-04 for the potential treatment of Ocular Rosacea and TP-05 as an oral tablet for the potential prevention of Lyme disease. The company was founded by Bobak Azamian and D. Michael Ackermann in 2017 and is headquartered in Irvine, CA.
- Founded
- 2017
- CEO
- Dr. Bobak Azamian, M.D.,PhD
- Employees
- 370
- Headquarters
- Irvine, California, United States of America
- Fiscal year end
- 12-31
- Website
- tarsusrx.com
Company profile
- Exchange
- US
- Symbol
- TARS
- Market-cap rank
- #2389
- Listing date
- 2020-10-16
- Market cap
- 3.44B
- Float cap
- 2.62B
- Shares out
- 46.79M
- Float shares
- 35.65M
Sectors & themes
Quote time 2026-10-08 07:00:14 · For reference only, not investment advice and not tailored to your situation.